DIA Biosimilars 2013

INSERM

Mutabilis receives $5.2M from E.U. for HIVINNOV project

Wednesday, September 19, 2012 11:06 AM

Mutabilis, a spin-off from INSERM that focuses on therapeutics for treating serious, hospital-acquired infections, has received $5.2 million of European funding for the HIVINNOV project, aimed at developing new antiretrovirals against HIV.

More... »

Cenduit: Now with Patient Reminders

Covance enters R&D collaboration

Thursday, January 19, 2012 08:30 AM

Covance, Inserm Transfert, a subsidiary of Inserm, and seed investment company Inserm Transfert Initiative have signed a four-year R&D collaboration.

More... »

CRF Health – eCOA Forum

Boston Scientific enrolls first patients in NECTAR-HF trial

Friday, September 30, 2011 11:11 AM

Boston Scientific has enrolled the first patients in its NECTAR-HF (neural cardiac therapy for heart failure) clinical trial.  NECTAR-HF is a prospective, randomized, international clinical feasibility study designed to assess preliminary safety and efficacy of chronic vagal nerve stimulation in heart failure patients.  The study will evaluate 96 patients with vagal nerve stimulator implants at multiple centers in Europe.

More... »

CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs